Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dermata Therapeutics, Inc. filings document a dermatology-focused operating company with common stock and publicly traded warrants, a direct-to-consumer skincare strategy and ongoing capital-structure activity. Recent Form 8-K reports cover annual and quarterly operating results, prospectus supplements for at-the-market common stock sales, private financing-related disclosure, and material agreements tied to the company's shift away from pharmaceutical development.
Dermata's proxy and governance filings address shareholder voting matters, board composition and corporate governance. Other current reports document changes in the independent registered public accounting firm, director resignation disclosures, going-concern context in auditor reports, and material-agreement disclosure involving the Villani license and the XYNGARI investigational new drug application.
Kyri K. Van Hoose, Chief Financial Officer of Dermata Therapeutics, Inc., filed a Schedule 13D reporting a significant equity stake in the company. As of May 27, 2026, she may be deemed to beneficially own 384,352 shares of common stock, representing 9.0% of Dermata’s 4,022,143 shares outstanding.
Her position consists of 130,423 common shares, warrants exercisable for 252,972 shares, and stock options exercisable for 957 shares, with additional options excluded because they are not exercisable within 60 days. A large portion of this stake stems from a December 23, 2025 private placement, where she purchased common stock and warrants on the same terms as institutional and accredited investors, mainly for investment purposes while reserving flexibility to change her holdings over time.
Dermata Therapeutics, Inc. registers an aggregate $100,000,000 shelf to offer common stock, preferred stock, warrants, debt securities, subscription rights and units.
The prospectus states the aggregate public offering price will not exceed $100,000,000, that offerings will be made from time to time on market-driven terms, and that the company’s common stock and certain warrants trade on Nasdaq under the symbols DRMA and DRMAW. The prospectus discloses a public float of $3,955,179.64 based on 3,189,661 public shares at a closing price of $1.24 per share and reports 4,022,143 shares of common stock outstanding as of May 21, 2026.
Dermata Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders, where all management proposals were approved. Stockholders amended the 2021 Omnibus Equity Incentive Plan to increase the maximum aggregate number of shares reserved for issuance under the plan to 402,214 shares.
They also approved, for Nasdaq Listing Rule 5635(d) purposes, the issuance of common shares underlying certain warrants in an amount equal to or in excess of 20% of the common stock outstanding immediately before those warrants were issued, as well as a repricing of warrants exercisable for up to 120,734 shares. Three Class II directors were elected, the independent auditor for the year ending December 31, 2026 was ratified, and an adjournment proposal was approved.
Dermata Therapeutics, Inc. proposes a shelf offering registering up to $100,000,000 of common stock, preferred stock, warrants, debt securities, subscription rights and units, to be offered from time to time.
The prospectus describes the company’s strategic shift from Rx dermatology to direct-to-consumer and B2B cosmetic skincare products using its Bioneedle ingredient derived from Spongilla lacustris, plans to launch a Foundational Treatment in mid-2026, and continued exploration of topical botulinum toxin applications. It discloses recent ATM sales of 824,283 shares for approximately $2.0 million, pro forma shares outstanding of 4,022,143 as of May 21, 2026, a public float of $3,955,179.64, and recent net losses of $1.8 million for Q1 2026 and $7.6 million for 2025.
Dermata Therapeutics, Inc. reporting persons disclosed beneficial ownership of 211,246 shares of common stock, representing 4.99% of the class. The position reflects shares issuable upon exercise of four warrants and is calculated using March 25, 2026 outstanding share data.
The filing states a blocker provision limits exercise of part of one warrant (Intracoastal Warrant 4), excluding 111,453 shares from the ownership total; without the blocker the reporting persons may be deemed to beneficially own 322,699 shares.
Dermata Therapeutics reported first quarter 2026 results while continuing its shift from drug development to direct-to-consumer skincare under the new Tome brand. The company plans a mid-2026 launch of its once-weekly Tome Foundational Treatment mask for skin renewal.
Dermata ended March 31, 2026 with $6.9 million in cash and cash equivalents and raised $2.0 million in net proceeds through an at-the-market financing facility. Research and development expenses fell to $0.4 million from $1.3 million a year earlier, while selling, general and administrative expenses increased to $1.5 million from $1.1 million, mainly from marketing, audit, and legal costs. Net loss narrowed to $1.8 million, or $0.48 per share, compared with $2.3 million, or $4.47 per share, and the company expects its cash to fund operations into the first quarter of 2027.
Dermata Therapeutics, Inc. ownership update: Bigger Capital Fund, LP and related reporting persons disclose beneficial ownership of 75,200 shares of Common Stock, representing 1.87% of the outstanding shares based on 4,022,143 shares outstanding as of March 30, 2026. The filing states this figure excludes multiple warrant positions (including 490,200 Series C and 490,200 Series D issuable shares held by Bigger Capital, and 189,084 DRMAW Public Warrants) that are subject to shareholder approval and a 4.99% beneficial ownership limitation. The Reporting Persons note they sold a portion of their Common Stock, including all Common Stock issuable upon exercise of Pre-Funded Warrants, and state they do not beneficially own at least 5.00% of the issuer as of April 22, 2026.